- Featured Product
- KD/KO Validated
CDK1 Polyclonal antibody
CDK1 Polyclonal Antibody for WB, IHC, IF/ICC, FC (Intra), ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse and More (3)
Applications
WB, IHC, IF/ICC, FC (Intra), ELISA
Conjugate
Unconjugated
Cat no : 10762-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | C2C12 cell, HeLa cells, C2C12 cells, Jurkat cells |
| Positive IHC detected in | human prostate cancer tissue, human breast cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HeLa cells |
| Positive FC (Intra) detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:250-1:1000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 69 publications below |
| IHC | See 3 publications below |
| IF | See 2 publications below |
Product Information
10762-1-AP targets CDK1 in WB, IHC, IF/ICC, FC (Intra), ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, pig, chicken, goat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | CDK1 fusion protein Ag1183 |
| Full Name | cell division cycle 2, G1 to S and G2 to M |
| Calculated Molecular Weight | 25 kDa |
| Observed Molecular Weight | 34 kDa |
| GenBank Accession Number | BC014563 |
| Gene Symbol | CDK1 |
| Gene ID (NCBI) | 983 |
| RRID | AB_2074898 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CDK1, also named as CDC2, belongs to the protein kinase superfamily, CMGC Ser/Thr protein kinase family and CDC2/CDKX subfamily. CDK1 plays a key role in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S-phase and mitosis. CDK1 is a catalytic subunit of the highly conserved protein kinase complex known as M-phase promoting factor (MPF), which is essential for G1/S and G2/M phase transitions of eukaryotic cell cycle. It is a component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II. Mitotic cyclins stably associate with CDK1 and function as regulatory subunits. CDK1 has 2 isoforms produced by alternative splicing with the molecular mass of 34 kDa and 27 kDa. This antibody may have cross reaction with CDK2.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for CDK1 antibody 10762-1-AP | Download protocol |
| IHC protocol for CDK1 antibody 10762-1-AP | Download protocol |
| IF protocol for CDK1 antibody 10762-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Biomed Pharmacother Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma. | ||
Mol Ther Nucleic Acids Inhibition of the lncRNA MIAT prevents podocyte injury and mitotic catastrophe in diabetic nephropathy. | ||
Cell Death Dis PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT. | ||
Cancers (Basel) Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib. | ||
Life Sci Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway |
